Prostate cancer and hypofractionation: really a new standard of care?

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results

“…As pointed out by Carrie and Tanguy ( 13 ), authors of the HYPRO study ( 5 - 7 ) came to a different conclusion using their hypofractionated schedule. There are, however, important differences in trial design and treatment implementation which may account for this.…”